Legend Capital Leads ~USD14m Pre-Series A for China’s GS Biotech
Source(s): 36Kr
Legend Capital led a ~CNY100m (~USD14m) pre-Series A for GS Biotech, a China-based developer of bio-based materials, with participation from Junsan Capital and Eastern Bell Capital. Read More